摘要
目的观察低分子肝素联合降纤酶治疗急性脑梗死的临床疗效。方法选择急性脑梗死患者122例,随机分为对照组和治疗组,对照组给予川芎嗪、低分子肝素治疗,治疗组在对照组基础上加降纤酶治疗。两组均于治疗前及治疗后14 d进行神经功能缺损评分,并观察不良反应。结果治疗14 d后神经功能缺损评分、总有效率对照组分别为(11.5±3.7)分、75.00%,治疗组分别为(7.2±3.3)分、91.94%,两组比较差异均有统计学意义(均P<0.05)。结论低分子肝素联合降纤酶治疗急性脑梗死疗效好,且无严重不良反应,值得临床推广应用。
Objective To investigate the clinical efficiency of low-molecular-weight heparin calcium with defibrase in treating patients with acute cerebral infarction.Methods 112 patients with acute cerebral infarction were randomly divided into two groups：control group（n=60） and treatment group（n=62）.Control group was treated with dehydrating agent,brain cell protective agent,Ligustrazine and low-molecular-weight heparin calcium,while treatment group with additional Defibrase.Both groups were assessed for ESS scores and adverse reactions before treatment and 14 days after treatment.Results After treatment,ESS scores and total effective rate were 11.5±3.7 and 75.00% respectively in the treatment group;7.2±3.3 and 91.94% respectively in the control group.Significant difference was found between the two groups（P0.05）.Conclusion Combined with defibrase,low-molecular-weight heparin calcium is more effective for acute cerebral infarction and has no severe adverse reaction,which is worthy of clinical application.
出处
《社区医学杂志》
2012年第5期5-6,共2页
Journal Of Community Medicine
关键词
急性脑梗死
低分子肝素
降纤酶
Acute cerebral infarction Low-molecular-weight heparin Defibrase
